| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Resistance, Viral | 45 | 2013 | 869 | 3.690 |
Why?
|
| HIV-1 | 125 | 2013 | 6963 | 3.560 |
Why?
|
| HIV Protease Inhibitors | 27 | 2012 | 432 | 2.240 |
Why?
|
| Anti-HIV Agents | 74 | 2013 | 4571 | 2.080 |
Why?
|
| HIV Infections | 121 | 2013 | 17575 | 1.850 |
Why?
|
| HIV Protease | 22 | 2012 | 98 | 1.670 |
Why?
|
| Zidovudine | 39 | 2008 | 625 | 1.610 |
Why?
|
| HIV Reverse Transcriptase | 29 | 2012 | 214 | 1.570 |
Why?
|
| Reverse Transcriptase Inhibitors | 37 | 2011 | 622 | 1.520 |
Why?
|
| Antiviral Agents | 35 | 2013 | 3064 | 1.440 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 13 | 2012 | 450 | 1.410 |
Why?
|
| HIV | 19 | 2011 | 1596 | 1.270 |
Why?
|
| Ritonavir | 13 | 2010 | 330 | 1.190 |
Why?
|
| Drug Resistance, Multiple, Viral | 8 | 2011 | 52 | 1.100 |
Why?
|
| Lamivudine | 26 | 2012 | 367 | 1.070 |
Why?
|
| Drug Resistance, Microbial | 37 | 2002 | 830 | 1.020 |
Why?
|
| RNA, Viral | 42 | 2013 | 2866 | 0.980 |
Why?
|
| Influenza, Human | 15 | 2013 | 1539 | 0.950 |
Why?
|
| Acquired Immunodeficiency Syndrome | 23 | 2009 | 2202 | 0.920 |
Why?
|
| Viral Load | 43 | 2013 | 3398 | 0.860 |
Why?
|
| Neuraminidase | 7 | 2013 | 195 | 0.820 |
Why?
|
| Thallium Radioisotopes | 20 | 1994 | 139 | 0.800 |
Why?
|
| Virus Replication | 26 | 2012 | 2458 | 0.740 |
Why?
|
| Pyrones | 5 | 2010 | 35 | 0.690 |
Why?
|
| Antiretroviral Therapy, Highly Active | 15 | 2012 | 1903 | 0.670 |
Why?
|
| Oseltamivir | 8 | 2013 | 75 | 0.650 |
Why?
|
| Saquinavir | 8 | 2001 | 29 | 0.620 |
Why?
|
| CD4 Lymphocyte Count | 37 | 2012 | 2596 | 0.610 |
Why?
|
| Hepatitis B, Chronic | 9 | 2012 | 413 | 0.590 |
Why?
|
| Coronary Disease | 37 | 2001 | 5924 | 0.580 |
Why?
|
| Pyrimidinones | 3 | 2009 | 386 | 0.580 |
Why?
|
| Indinavir | 8 | 2009 | 73 | 0.550 |
Why?
|
| Nevirapine | 9 | 2009 | 273 | 0.540 |
Why?
|
| Zanamivir | 4 | 2012 | 21 | 0.530 |
Why?
|
| Dipyridamole | 10 | 1992 | 143 | 0.510 |
Why?
|
| Amino Acid Substitution | 10 | 2012 | 1742 | 0.500 |
Why?
|
| RNA-Directed DNA Polymerase | 10 | 2009 | 223 | 0.490 |
Why?
|
| Exercise Test | 26 | 2001 | 2186 | 0.480 |
Why?
|
| Computer Communication Networks | 2 | 2008 | 295 | 0.480 |
Why?
|
| Hepatitis B Surface Antigens | 8 | 2012 | 294 | 0.480 |
Why?
|
| Mutation | 48 | 2012 | 30228 | 0.470 |
Why?
|
| Hepatitis B virus | 8 | 2012 | 530 | 0.440 |
Why?
|
| Codon | 12 | 2007 | 599 | 0.430 |
Why?
|
| DNA, Viral | 19 | 2012 | 2205 | 0.420 |
Why?
|
| Adenine | 4 | 2013 | 993 | 0.420 |
Why?
|
| Pyridines | 12 | 2010 | 2889 | 0.400 |
Why?
|
| Superinfection | 1 | 2012 | 63 | 0.400 |
Why?
|
| Thallium | 10 | 1992 | 100 | 0.390 |
Why?
|
| HIV Antigens | 7 | 2000 | 328 | 0.380 |
Why?
|
| Acyclovir | 1 | 2012 | 267 | 0.370 |
Why?
|
| Anti-Retroviral Agents | 5 | 2011 | 1794 | 0.360 |
Why?
|
| Diltiazem | 2 | 2006 | 132 | 0.360 |
Why?
|
| Herpesvirus 2, Human | 1 | 2012 | 191 | 0.360 |
Why?
|
| CD4-Positive T-Lymphocytes | 13 | 2009 | 4411 | 0.350 |
Why?
|
| Heart | 22 | 1994 | 4449 | 0.350 |
Why?
|
| Drug Therapy, Combination | 28 | 2012 | 6318 | 0.350 |
Why?
|
| Expert Systems | 2 | 2010 | 79 | 0.340 |
Why?
|
| Interferon-alpha | 8 | 2012 | 910 | 0.340 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2006 | 1360 | 0.330 |
Why?
|
| Pseudomonas | 3 | 1995 | 124 | 0.330 |
Why?
|
| Angina Pectoris | 9 | 1993 | 960 | 0.330 |
Why?
|
| Viruses | 4 | 2012 | 373 | 0.330 |
Why?
|
| Zalcitabine | 9 | 1998 | 43 | 0.320 |
Why?
|
| Radionuclide Imaging | 37 | 1994 | 1998 | 0.320 |
Why?
|
| Herpes Simplex | 1 | 2012 | 470 | 0.310 |
Why?
|
| Integrase Inhibitors | 1 | 2008 | 12 | 0.300 |
Why?
|
| Europe | 15 | 2013 | 3439 | 0.300 |
Why?
|
| Genotype | 31 | 2012 | 13042 | 0.300 |
Why?
|
| Medical Informatics Computing | 1 | 2008 | 23 | 0.300 |
Why?
|
| Nitroglycerin | 3 | 2006 | 332 | 0.280 |
Why?
|
| Disease Notification | 1 | 2007 | 95 | 0.280 |
Why?
|
| Deoxycytidine | 2 | 2013 | 888 | 0.280 |
Why?
|
| Humans | 275 | 2013 | 768393 | 0.280 |
Why?
|
| Hepatitis B e Antigens | 6 | 2012 | 135 | 0.280 |
Why?
|
| Molecular Sequence Data | 29 | 2011 | 17626 | 0.280 |
Why?
|
| Amino Acid Sequence | 26 | 2009 | 13423 | 0.270 |
Why?
|
| Coronary Vasospasm | 2 | 2006 | 81 | 0.270 |
Why?
|
| Genes, pol | 5 | 2012 | 52 | 0.270 |
Why?
|
| Sentinel Surveillance | 2 | 2011 | 292 | 0.270 |
Why?
|
| Biological Evolution | 2 | 2011 | 1078 | 0.270 |
Why?
|
| Phylogeny | 9 | 2012 | 2843 | 0.270 |
Why?
|
| Polyethylene Glycols | 5 | 2012 | 1195 | 0.270 |
Why?
|
| Virus Latency | 1 | 2009 | 360 | 0.260 |
Why?
|
| Microbial Sensitivity Tests | 10 | 2013 | 1961 | 0.260 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2010 | 590 | 0.260 |
Why?
|
| Disease Outbreaks | 6 | 2010 | 1762 | 0.250 |
Why?
|
| Point Mutation | 6 | 2009 | 1594 | 0.250 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2008 | 1141 | 0.250 |
Why?
|
| Myocardial Contraction | 14 | 1994 | 1527 | 0.240 |
Why?
|
| Treatment Failure | 8 | 2012 | 2663 | 0.240 |
Why?
|
| Viremia | 5 | 2010 | 725 | 0.240 |
Why?
|
| Netherlands | 10 | 2012 | 2274 | 0.240 |
Why?
|
| Bepridil | 4 | 1993 | 12 | 0.230 |
Why?
|
| Drug Resistance, Multiple | 4 | 2003 | 255 | 0.230 |
Why?
|
| Electrocardiography | 23 | 2006 | 6409 | 0.230 |
Why?
|
| Organotechnetium Compounds | 4 | 1992 | 133 | 0.230 |
Why?
|
| Coronary Circulation | 4 | 2008 | 1617 | 0.220 |
Why?
|
| Systems Integration | 1 | 2005 | 430 | 0.220 |
Why?
|
| HIV Antibodies | 10 | 1997 | 1341 | 0.220 |
Why?
|
| Mutation, Missense | 5 | 2012 | 2593 | 0.210 |
Why?
|
| Base Sequence | 19 | 2010 | 12422 | 0.210 |
Why?
|
| Coronary Artery Bypass | 8 | 2006 | 2194 | 0.200 |
Why?
|
| Immunologic Memory | 1 | 2009 | 1374 | 0.200 |
Why?
|
| Virus Diseases | 4 | 2012 | 723 | 0.190 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 3 | 2012 | 215 | 0.190 |
Why?
|
| Procaine | 1 | 2001 | 60 | 0.190 |
Why?
|
| Radioisotopes | 9 | 1987 | 517 | 0.180 |
Why?
|
| Antigens, CD | 4 | 2000 | 4031 | 0.180 |
Why?
|
| Male | 137 | 2013 | 364902 | 0.180 |
Why?
|
| Nifedipine | 2 | 1991 | 220 | 0.170 |
Why?
|
| Homeodomain Proteins | 3 | 2000 | 2429 | 0.170 |
Why?
|
| Evolution, Molecular | 7 | 2007 | 1893 | 0.170 |
Why?
|
| Proviruses | 5 | 1998 | 320 | 0.170 |
Why?
|
| Propranolol | 5 | 1992 | 493 | 0.170 |
Why?
|
| Guanine | 2 | 2011 | 280 | 0.170 |
Why?
|
| Ventricular Function, Left | 8 | 1994 | 3941 | 0.170 |
Why?
|
| Disease Transmission, Infectious | 1 | 2005 | 562 | 0.170 |
Why?
|
| Receptors, HIV | 1 | 2000 | 159 | 0.170 |
Why?
|
| Adult | 94 | 2013 | 223640 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 4588 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 15 | 2009 | 6085 | 0.160 |
Why?
|
| Heparin | 1 | 2006 | 1636 | 0.160 |
Why?
|
| Middle Aged | 100 | 2013 | 223491 | 0.160 |
Why?
|
| Nitriles | 4 | 1992 | 984 | 0.160 |
Why?
|
| Sequence Analysis, DNA | 8 | 2010 | 4775 | 0.150 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 2734 | 0.150 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2008 | 1177 | 0.150 |
Why?
|
| Mutagenesis, Insertional | 4 | 2008 | 662 | 0.150 |
Why?
|
| Cardiac Output | 8 | 1998 | 838 | 0.150 |
Why?
|
| Anesthesia, Spinal | 1 | 2001 | 282 | 0.150 |
Why?
|
| Peptide Hydrolases | 2 | 2012 | 610 | 0.150 |
Why?
|
| Genes, Homeobox | 2 | 1996 | 289 | 0.150 |
Why?
|
| HIV Seropositivity | 7 | 1996 | 962 | 0.150 |
Why?
|
| Fentanyl | 1 | 2001 | 450 | 0.150 |
Why?
|
| Female | 114 | 2013 | 397089 | 0.140 |
Why?
|
| Genes, env | 2 | 2012 | 95 | 0.140 |
Why?
|
| Host-Parasite Interactions | 2 | 1996 | 303 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2011 | 876 | 0.140 |
Why?
|
| Drug Administration Schedule | 6 | 2010 | 4859 | 0.140 |
Why?
|
| Genes | 2 | 2001 | 1824 | 0.140 |
Why?
|
| HIV Core Protein p24 | 12 | 1997 | 247 | 0.140 |
Why?
|
| Lectins, C-Type | 1 | 2000 | 591 | 0.140 |
Why?
|
| Myocardial Infarction | 15 | 1993 | 11516 | 0.140 |
Why?
|
| Bacterial Proteins | 3 | 1995 | 3838 | 0.130 |
Why?
|
| Disease Progression | 4 | 2012 | 13646 | 0.130 |
Why?
|
| Heart Diseases | 3 | 2008 | 2819 | 0.130 |
Why?
|
| Hepatitis B | 4 | 2011 | 708 | 0.130 |
Why?
|
| Chest Pain | 3 | 2006 | 1099 | 0.130 |
Why?
|
| DNA Mutational Analysis | 6 | 2012 | 4120 | 0.130 |
Why?
|
| Nicardipine | 3 | 1991 | 60 | 0.130 |
Why?
|
| Enzyme Inhibitors | 3 | 2012 | 3722 | 0.130 |
Why?
|
| Viral Proteins | 5 | 2012 | 1802 | 0.130 |
Why?
|
| Homosexuality | 3 | 1992 | 268 | 0.130 |
Why?
|
| Vascular Surgical Procedures | 4 | 1990 | 1515 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1996 | 286 | 0.120 |
Why?
|
| Stroke Volume | 17 | 1994 | 5619 | 0.120 |
Why?
|
| Drug Monitoring | 4 | 2012 | 964 | 0.120 |
Why?
|
| Genetic Variation | 11 | 2007 | 6606 | 0.120 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1998 | 664 | 0.120 |
Why?
|
| Didanosine | 5 | 1998 | 151 | 0.120 |
Why?
|
| Multigene Family | 2 | 1995 | 1082 | 0.120 |
Why?
|
| Cloning, Molecular | 6 | 2000 | 4168 | 0.120 |
Why?
|
| Lymphocyte Activation | 5 | 2009 | 5496 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2002 | 4646 | 0.110 |
Why?
|
| Clinical Trials as Topic | 8 | 2006 | 8051 | 0.110 |
Why?
|
| Anesthetics, Local | 1 | 2001 | 1004 | 0.110 |
Why?
|
| Calcium Channel Blockers | 3 | 2006 | 692 | 0.110 |
Why?
|
| Hepacivirus | 3 | 2011 | 1342 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 1 | 2000 | 1614 | 0.110 |
Why?
|
| Sequence Alignment | 8 | 2006 | 2176 | 0.110 |
Why?
|
| Time Factors | 21 | 2012 | 40272 | 0.110 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1998 | 640 | 0.110 |
Why?
|
| Computational Biology | 1 | 2005 | 3543 | 0.110 |
Why?
|
| Gated Blood-Pool Imaging | 7 | 1992 | 44 | 0.110 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1998 | 591 | 0.110 |
Why?
|
| Interferon Type I | 3 | 2010 | 569 | 0.110 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2006 | 2185 | 0.110 |
Why?
|
| Genes, Bacterial | 2 | 1995 | 1076 | 0.110 |
Why?
|
| Polymorphism, Genetic | 3 | 2012 | 4250 | 0.100 |
Why?
|
| Epitopes | 5 | 1993 | 2525 | 0.100 |
Why?
|
| Cardiac Output, Low | 2 | 1992 | 191 | 0.100 |
Why?
|
| Antihypertensive Agents | 2 | 1992 | 2027 | 0.100 |
Why?
|
| Plants | 1 | 1994 | 332 | 0.100 |
Why?
|
| Hypertension | 5 | 1994 | 8615 | 0.100 |
Why?
|
| Recombinant Proteins | 11 | 2012 | 6510 | 0.100 |
Why?
|
| Sequence Homology, Amino Acid | 8 | 2001 | 2750 | 0.100 |
Why?
|
| Treatment Outcome | 23 | 2013 | 65379 | 0.100 |
Why?
|
| Atenolol | 1 | 1992 | 99 | 0.100 |
Why?
|
| Peptides | 5 | 2007 | 4353 | 0.100 |
Why?
|
| Diastole | 8 | 1994 | 784 | 0.100 |
Why?
|
| DNA, Complementary | 2 | 2009 | 1992 | 0.100 |
Why?
|
| Orthomyxoviridae Infections | 2 | 2011 | 255 | 0.100 |
Why?
|
| Hepatitis C | 4 | 2011 | 1593 | 0.100 |
Why?
|
| Data Collection | 1 | 2001 | 3324 | 0.100 |
Why?
|
| DNA, Bacterial | 2 | 1994 | 1479 | 0.100 |
Why?
|
| Hemodynamics | 14 | 1994 | 4199 | 0.090 |
Why?
|
| Xenotropic murine leukemia virus-related virus | 1 | 2010 | 4 | 0.090 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 162 | 0.090 |
Why?
|
| Orthomyxoviridae | 2 | 2009 | 148 | 0.090 |
Why?
|
| Phenotype | 16 | 2011 | 16721 | 0.090 |
Why?
|
| Technetium Tc 99m Sestamibi | 5 | 1992 | 184 | 0.090 |
Why?
|
| Cell Line | 10 | 2011 | 15597 | 0.090 |
Why?
|
| Retroviridae Infections | 1 | 2010 | 148 | 0.090 |
Why?
|
| Nitroprusside | 7 | 1994 | 272 | 0.090 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2011 | 83 | 0.090 |
Why?
|
| Viral Tropism | 1 | 2011 | 102 | 0.090 |
Why?
|
| Cyclohexanes | 1 | 2011 | 152 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 2 | 2000 | 4414 | 0.090 |
Why?
|
| Radionuclide Angiography | 5 | 1994 | 23 | 0.090 |
Why?
|
| Dipeptides | 1 | 1992 | 386 | 0.090 |
Why?
|
| Proline | 1 | 1992 | 455 | 0.090 |
Why?
|
| Environmental Exposure | 1 | 2005 | 4528 | 0.090 |
Why?
|
| Delavirdine | 3 | 1999 | 7 | 0.090 |
Why?
|
| Sulfonamides | 5 | 2010 | 1980 | 0.090 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2010 | 85 | 0.080 |
Why?
|
| Directed Molecular Evolution | 2 | 2008 | 165 | 0.080 |
Why?
|
| Homosexuality, Male | 3 | 2010 | 1345 | 0.080 |
Why?
|
| Transients and Migrants | 1 | 2012 | 170 | 0.080 |
Why?
|
| Blood Pressure | 14 | 2001 | 8541 | 0.080 |
Why?
|
| Sequence Analysis, Protein | 1 | 2010 | 265 | 0.080 |
Why?
|
| Lung | 7 | 1991 | 10089 | 0.080 |
Why?
|
| Containment of Biohazards | 1 | 2009 | 39 | 0.080 |
Why?
|
| Sequence Homology | 1 | 2009 | 199 | 0.080 |
Why?
|
| Inhibitory Concentration 50 | 4 | 2008 | 466 | 0.080 |
Why?
|
| HIV Envelope Protein gp41 | 2 | 2006 | 306 | 0.080 |
Why?
|
| Virology | 2 | 2001 | 76 | 0.080 |
Why?
|
| Influenza A virus | 1 | 2013 | 460 | 0.080 |
Why?
|
| Heart Function Tests | 1 | 1990 | 318 | 0.080 |
Why?
|
| Zimbabwe | 1 | 2009 | 135 | 0.080 |
Why?
|
| Systole | 7 | 1994 | 937 | 0.080 |
Why?
|
| Fatal Outcome | 2 | 2010 | 1837 | 0.080 |
Why?
|
| Dendritic Cells | 1 | 2000 | 2749 | 0.080 |
Why?
|
| Hygiene | 1 | 2009 | 95 | 0.080 |
Why?
|
| Pandemics | 4 | 2012 | 8753 | 0.080 |
Why?
|
| Peptide Fragments | 5 | 2006 | 5151 | 0.080 |
Why?
|
| Databases, Protein | 1 | 2010 | 385 | 0.080 |
Why?
|
| Retroviridae | 1 | 2010 | 849 | 0.080 |
Why?
|
| Polyradiculoneuropathy | 1 | 1988 | 65 | 0.070 |
Why?
|
| Hydroxyurea | 2 | 2000 | 284 | 0.070 |
Why?
|
| Feedback, Physiological | 1 | 2010 | 481 | 0.070 |
Why?
|
| Preoperative Care | 7 | 1992 | 2258 | 0.070 |
Why?
|
| Infusions, Intravenous | 2 | 2011 | 2226 | 0.070 |
Why?
|
| Myocardium | 8 | 1990 | 4788 | 0.070 |
Why?
|
| Viral Envelope Proteins | 2 | 2007 | 641 | 0.070 |
Why?
|
| Gene Products, gag | 2 | 2007 | 317 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2012 | 620 | 0.070 |
Why?
|
| Artificial Intelligence | 3 | 2008 | 2661 | 0.070 |
Why?
|
| Plasmapheresis | 1 | 1988 | 207 | 0.070 |
Why?
|
| Chromosome Mapping | 4 | 2005 | 4622 | 0.070 |
Why?
|
| Ventricular Function | 3 | 1998 | 406 | 0.070 |
Why?
|
| DNA Primers | 4 | 1999 | 2825 | 0.070 |
Why?
|
| Epidemics | 1 | 2013 | 517 | 0.070 |
Why?
|
| Aged | 46 | 2013 | 171562 | 0.070 |
Why?
|
| Genome, Viral | 2 | 2010 | 673 | 0.070 |
Why?
|
| Heart Rate | 12 | 1992 | 4218 | 0.070 |
Why?
|
| Contact Tracing | 1 | 2009 | 275 | 0.070 |
Why?
|
| Protein Interaction Mapping | 1 | 2010 | 612 | 0.070 |
Why?
|
| Vasodilator Agents | 2 | 2006 | 990 | 0.070 |
Why?
|
| World Health Organization | 2 | 2011 | 1327 | 0.070 |
Why?
|
| Child, Preschool | 11 | 2013 | 42650 | 0.070 |
Why?
|
| Acetophenones | 2 | 1997 | 52 | 0.070 |
Why?
|
| Vascular Resistance | 4 | 1993 | 940 | 0.070 |
Why?
|
| Follow-Up Studies | 19 | 2012 | 39407 | 0.070 |
Why?
|
| Pyrrolidines | 2 | 1985 | 340 | 0.070 |
Why?
|
| Membrane Fusion | 1 | 2007 | 265 | 0.070 |
Why?
|
| Computer Systems | 1 | 2008 | 470 | 0.070 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1998 | 2537 | 0.070 |
Why?
|
| Ventriculography, First-Pass | 2 | 1998 | 20 | 0.060 |
Why?
|
| Respiratory Tract Infections | 2 | 2012 | 1014 | 0.060 |
Why?
|
| Adolescent | 20 | 2013 | 89184 | 0.060 |
Why?
|
| Plasma | 1 | 2009 | 585 | 0.060 |
Why?
|
| Double-Blind Method | 11 | 2010 | 12456 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2013 | 1187 | 0.060 |
Why?
|
| Coronavirus | 1 | 2007 | 156 | 0.060 |
Why?
|
| Protease Inhibitors | 3 | 1999 | 752 | 0.060 |
Why?
|
| Triazoles | 1 | 2011 | 904 | 0.060 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2005 | 28 | 0.060 |
Why?
|
| Needlestick Injuries | 1 | 2005 | 71 | 0.060 |
Why?
|
| Blotting, Western | 4 | 2010 | 5037 | 0.060 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2006 | 223 | 0.060 |
Why?
|
| Host-Pathogen Interactions | 2 | 2010 | 1468 | 0.060 |
Why?
|
| Hepatitis | 1 | 2007 | 228 | 0.060 |
Why?
|
| Frameshift Mutation | 1 | 2007 | 393 | 0.060 |
Why?
|
| Analgesics, Opioid | 1 | 2001 | 3836 | 0.060 |
Why?
|
| Coronary Vessels | 4 | 2006 | 3125 | 0.060 |
Why?
|
| Acetamides | 2 | 1997 | 260 | 0.060 |
Why?
|
| Sensitivity and Specificity | 7 | 2013 | 14737 | 0.060 |
Why?
|
| Viral Vaccines | 1 | 1990 | 596 | 0.060 |
Why?
|
| Membrane Glycoproteins | 3 | 2007 | 3712 | 0.060 |
Why?
|
| Postoperative Complications | 6 | 1991 | 15881 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 1995 | 7599 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 1996 | 3579 | 0.060 |
Why?
|
| Geography | 1 | 2006 | 654 | 0.060 |
Why?
|
| Respiratory Tract Diseases | 1 | 2009 | 748 | 0.050 |
Why?
|
| HIV Envelope Protein gp120 | 3 | 2000 | 925 | 0.050 |
Why?
|
| Immunoblotting | 1 | 2007 | 1647 | 0.050 |
Why?
|
| Prevalence | 5 | 2013 | 15872 | 0.050 |
Why?
|
| South Africa | 1 | 2009 | 1871 | 0.050 |
Why?
|
| Predictive Value of Tests | 10 | 2011 | 15455 | 0.050 |
Why?
|
| Genetic Complementation Test | 2 | 1995 | 557 | 0.050 |
Why?
|
| Physical Exertion | 6 | 1989 | 669 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2009 | 1194 | 0.050 |
Why?
|
| Condoms | 1 | 2005 | 338 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2002 | 1813 | 0.050 |
Why?
|
| Cystic Fibrosis | 1 | 2012 | 1285 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2010 | 1558 | 0.050 |
Why?
|
| Animals | 22 | 2013 | 169337 | 0.050 |
Why?
|
| Capsules | 2 | 2000 | 193 | 0.050 |
Why?
|
| Prognosis | 17 | 2001 | 30022 | 0.050 |
Why?
|
| Ki-67 Antigen | 3 | 2000 | 628 | 0.050 |
Why?
|
| Cluster Analysis | 3 | 2010 | 2728 | 0.050 |
Why?
|
| ADP-ribosyl Cyclase | 2 | 2000 | 38 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2007 | 1753 | 0.050 |
Why?
|
| Equipment Failure | 1 | 2005 | 585 | 0.050 |
Why?
|
| Infant | 9 | 2013 | 36510 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2009 | 857 | 0.050 |
Why?
|
| NAD+ Nucleosidase | 2 | 2000 | 43 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 1998 | 9261 | 0.050 |
Why?
|
| Binding Sites | 4 | 2012 | 6017 | 0.050 |
Why?
|
| Atrial Natriuretic Factor | 2 | 1994 | 350 | 0.050 |
Why?
|
| T-Lymphocytes | 5 | 2011 | 10267 | 0.050 |
Why?
|
| Stavudine | 1 | 2002 | 85 | 0.050 |
Why?
|
| Biometry | 1 | 2005 | 565 | 0.050 |
Why?
|
| Virulence | 2 | 2011 | 1298 | 0.050 |
Why?
|
| Regression Analysis | 8 | 2010 | 6350 | 0.050 |
Why?
|
| Nelfinavir | 1 | 2001 | 68 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 5 | 2008 | 1682 | 0.050 |
Why?
|
| Thrombolytic Therapy | 1 | 1990 | 2050 | 0.050 |
Why?
|
| Tissue Distribution | 4 | 2001 | 2299 | 0.050 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2001 | 35 | 0.050 |
Why?
|
| Rest | 6 | 1992 | 951 | 0.050 |
Why?
|
| Giant Cells | 2 | 1998 | 187 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2010 | 24318 | 0.050 |
Why?
|
| Rare Diseases | 1 | 2006 | 630 | 0.050 |
Why?
|
| Cytopathogenic Effect, Viral | 2 | 2008 | 152 | 0.040 |
Why?
|
| Open Reading Frames | 2 | 1995 | 812 | 0.040 |
Why?
|
| Prospective Studies | 13 | 2013 | 54920 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 1515 | 0.040 |
Why?
|
| Lymphocyte Count | 2 | 2002 | 793 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2001 | 318 | 0.040 |
Why?
|
| Coronary Stenosis | 1 | 2006 | 802 | 0.040 |
Why?
|
| beta 2-Microglobulin | 2 | 1998 | 329 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2006 | 2079 | 0.040 |
Why?
|
| Hypotension | 1 | 2006 | 889 | 0.040 |
Why?
|
| Hybrid Cells | 1 | 2000 | 421 | 0.040 |
Why?
|
| Y Chromosome | 1 | 2001 | 205 | 0.040 |
Why?
|
| Ferrets | 2 | 2011 | 181 | 0.040 |
Why?
|
| Exercise | 3 | 1998 | 5946 | 0.040 |
Why?
|
| Valine | 3 | 1996 | 410 | 0.040 |
Why?
|
| Drug Design | 1 | 2005 | 1046 | 0.040 |
Why?
|
| Protein Conformation | 4 | 2012 | 3955 | 0.040 |
Why?
|
| Aortic Valve Insufficiency | 2 | 1983 | 577 | 0.040 |
Why?
|
| Retroviridae Proteins | 2 | 1989 | 94 | 0.040 |
Why?
|
| Software | 3 | 2009 | 4453 | 0.040 |
Why?
|
| Antigens, Differentiation | 2 | 2000 | 921 | 0.040 |
Why?
|
| Longitudinal Studies | 5 | 2009 | 14784 | 0.040 |
Why?
|
| Pattern Recognition, Automated | 1 | 2005 | 998 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2000 | 313 | 0.040 |
Why?
|
| Models, Biological | 7 | 2013 | 9493 | 0.040 |
Why?
|
| Exercise Tolerance | 2 | 1994 | 848 | 0.040 |
Why?
|
| Thiazoles | 2 | 1996 | 1542 | 0.040 |
Why?
|
| Africa | 3 | 2012 | 726 | 0.040 |
Why?
|
| Tetrazolium Salts | 2 | 1996 | 92 | 0.040 |
Why?
|
| Blood Volume | 3 | 1990 | 546 | 0.040 |
Why?
|
| Transfection | 1 | 2007 | 5764 | 0.040 |
Why?
|
| Alanine Transaminase | 2 | 2012 | 605 | 0.040 |
Why?
|
| Critical Illness | 1 | 2011 | 2755 | 0.040 |
Why?
|
| Blotting, Northern | 1 | 2000 | 1553 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 5538 | 0.040 |
Why?
|
| HeLa Cells | 2 | 1996 | 3088 | 0.040 |
Why?
|
| Lectins | 1 | 2000 | 490 | 0.040 |
Why?
|
| Pneumonia | 1 | 2010 | 2163 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 2006 | 1525 | 0.040 |
Why?
|
| Oxygen Radioisotopes | 1 | 1977 | 75 | 0.040 |
Why?
|
| Gene Products, env | 1 | 1998 | 250 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2008 | 2598 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 1995 | 9614 | 0.040 |
Why?
|
| X Chromosome | 1 | 2001 | 819 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2001 | 529 | 0.040 |
Why?
|
| Gene Expression | 3 | 2001 | 7598 | 0.040 |
Why?
|
| Stress, Physiological | 3 | 1991 | 1410 | 0.040 |
Why?
|
| Back Pain | 1 | 2001 | 547 | 0.030 |
Why?
|
| Specialization | 1 | 2002 | 781 | 0.030 |
Why?
|
| Mathematical Computing | 1 | 1997 | 142 | 0.030 |
Why?
|
| Heart Ventricles | 7 | 1998 | 3838 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2003 | 1277 | 0.030 |
Why?
|
| Coronary Angiography | 6 | 1994 | 4537 | 0.030 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1998 | 462 | 0.030 |
Why?
|
| AIDS Dementia Complex | 1 | 1997 | 155 | 0.030 |
Why?
|
| Algorithms | 7 | 2009 | 14154 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1998 | 584 | 0.030 |
Why?
|
| Risk | 5 | 2009 | 9636 | 0.030 |
Why?
|
| Developing Countries | 1 | 2008 | 2903 | 0.030 |
Why?
|
| Methylurea Compounds | 1 | 1995 | 3 | 0.030 |
Why?
|
| Stereoisomerism | 2 | 1993 | 612 | 0.030 |
Why?
|
| Myotonic Dystrophy | 1 | 1996 | 80 | 0.030 |
Why?
|
| Electroporation | 1 | 1996 | 236 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2001 | 1082 | 0.030 |
Why?
|
| Proteins | 1 | 2010 | 6006 | 0.030 |
Why?
|
| Perfusion | 3 | 1992 | 1402 | 0.030 |
Why?
|
| Thymus Gland | 1 | 2000 | 1266 | 0.030 |
Why?
|
| Transcription Factors | 1 | 1995 | 12166 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2001 | 12805 | 0.030 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 1976 | 140 | 0.030 |
Why?
|
| Risk Factors | 14 | 2013 | 74962 | 0.030 |
Why?
|
| Occupational Exposure | 1 | 2005 | 1817 | 0.030 |
Why?
|
| Flagella | 1 | 1995 | 97 | 0.030 |
Why?
|
| Infant, Newborn | 6 | 2009 | 26411 | 0.030 |
Why?
|
| Recombination, Genetic | 2 | 1996 | 1526 | 0.030 |
Why?
|
| Recurrence | 2 | 2010 | 8506 | 0.030 |
Why?
|
| Potassium Compounds | 2 | 1985 | 42 | 0.030 |
Why?
|
| Child | 12 | 2013 | 80891 | 0.030 |
Why?
|
| Pulmonary Wedge Pressure | 3 | 1991 | 275 | 0.030 |
Why?
|
| Retrospective Studies | 9 | 2011 | 81801 | 0.030 |
Why?
|
| Reproducibility of Results | 5 | 2012 | 20224 | 0.030 |
Why?
|
| Echocardiography | 2 | 2001 | 5044 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2010 | 8075 | 0.030 |
Why?
|
| Ventricular Function, Right | 1 | 1998 | 628 | 0.030 |
Why?
|
| Physician's Role | 1 | 2001 | 926 | 0.030 |
Why?
|
| Xanthomonas campestris | 1 | 1993 | 7 | 0.030 |
Why?
|
| Triglycerides | 1 | 2001 | 2465 | 0.030 |
Why?
|
| Isoleucine | 1 | 1993 | 112 | 0.030 |
Why?
|
| Dogs | 5 | 2011 | 3846 | 0.030 |
Why?
|
| Kinetics | 4 | 2010 | 6333 | 0.030 |
Why?
|
| Medicine | 1 | 2002 | 948 | 0.030 |
Why?
|
| Seasons | 2 | 2009 | 1526 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 3 | 2011 | 7453 | 0.030 |
Why?
|
| Incidence | 5 | 2012 | 21544 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1994 | 849 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1977 | 1149 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 2000 | 896 | 0.030 |
Why?
|
| Angiography | 3 | 1989 | 1598 | 0.030 |
Why?
|
| Fosinopril | 1 | 1992 | 7 | 0.030 |
Why?
|
| Pregnancy | 5 | 2006 | 30200 | 0.030 |
Why?
|
| Protein Sorting Signals | 1 | 1993 | 274 | 0.030 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1997 | 628 | 0.030 |
Why?
|
| Lisinopril | 1 | 1992 | 60 | 0.030 |
Why?
|
| Heart Arrest, Induced | 2 | 1985 | 361 | 0.030 |
Why?
|
| Zambia | 1 | 2013 | 273 | 0.030 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 1993 | 110 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2001 | 1883 | 0.020 |
Why?
|
| Indonesia | 1 | 2012 | 131 | 0.020 |
Why?
|
| HIV Seronegativity | 2 | 2005 | 210 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 1993 | 575 | 0.020 |
Why?
|
| Plant Diseases | 1 | 1993 | 184 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 13020 | 0.020 |
Why?
|
| Selection, Genetic | 2 | 2011 | 877 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 1994 | 9063 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 1993 | 1605 | 0.020 |
Why?
|
| Adamantane | 1 | 2012 | 148 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2011 | 10377 | 0.020 |
Why?
|
| Heart Septum | 1 | 1992 | 304 | 0.020 |
Why?
|
| Tyrosine | 1 | 1996 | 1428 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2000 | 2568 | 0.020 |
Why?
|
| HIV Integrase | 1 | 2012 | 122 | 0.020 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1996 | 530 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 1998 | 839 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2012 | 396 | 0.020 |
Why?
|
| Neutralization Tests | 2 | 1993 | 739 | 0.020 |
Why?
|
| Cysteine | 1 | 1996 | 895 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 1991 | 163 | 0.020 |
Why?
|
| Models, Molecular | 3 | 2007 | 5404 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2000 | 2819 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2006 | 4843 | 0.020 |
Why?
|
| Norepinephrine | 2 | 1994 | 900 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2001 | 3581 | 0.020 |
Why?
|
| Research Design | 1 | 2006 | 6210 | 0.020 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2010 | 87 | 0.020 |
Why?
|
| Ribavirin | 1 | 2012 | 395 | 0.020 |
Why?
|
| Laboratories | 2 | 2009 | 463 | 0.020 |
Why?
|
| Technetium | 3 | 1989 | 326 | 0.020 |
Why?
|
| Latin America | 1 | 2012 | 416 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 1997 | 1033 | 0.020 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1993 | 403 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2000 | 2708 | 0.020 |
Why?
|
| Heart Defects, Congenital | 2 | 1977 | 4713 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2012 | 489 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1994 | 1539 | 0.020 |
Why?
|
| Multivariate Analysis | 6 | 2002 | 12092 | 0.020 |
Why?
|
| Asia | 1 | 2012 | 627 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 4 | 1991 | 2258 | 0.020 |
Why?
|
| Sputum | 1 | 2012 | 512 | 0.020 |
Why?
|
| Cohort Studies | 7 | 2009 | 41795 | 0.020 |
Why?
|
| DNA | 2 | 2001 | 7211 | 0.020 |
Why?
|
| Aged, 80 and over | 6 | 2013 | 59686 | 0.020 |
Why?
|
| PubMed | 1 | 2010 | 130 | 0.020 |
Why?
|
| Cardiotonic Agents | 1 | 1992 | 544 | 0.020 |
Why?
|
| Piperazines | 2 | 1997 | 2552 | 0.020 |
Why?
|
| Deltaretrovirus Antigens | 1 | 1988 | 3 | 0.020 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2010 | 217 | 0.020 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2009 | 90 | 0.020 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 1989 | 61 | 0.020 |
Why?
|
| Virus Shedding | 1 | 2009 | 110 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2000 | 3612 | 0.020 |
Why?
|
| Models, Cardiovascular | 2 | 1992 | 984 | 0.020 |
Why?
|
| Collateral Circulation | 1 | 1989 | 291 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 1988 | 372 | 0.020 |
Why?
|
| HTLV-I Infections | 1 | 1988 | 104 | 0.020 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2009 | 161 | 0.020 |
Why?
|
| Nucleosides | 2 | 2000 | 131 | 0.020 |
Why?
|
| Random Allocation | 4 | 1985 | 2397 | 0.020 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1994 | 843 | 0.020 |
Why?
|
| Stochastic Processes | 2 | 2000 | 359 | 0.020 |
Why?
|
| Monocytes | 1 | 1997 | 2595 | 0.020 |
Why?
|
| North America | 1 | 2012 | 1290 | 0.020 |
Why?
|
| Thymidine | 1 | 1988 | 297 | 0.020 |
Why?
|
| DNA Replication | 2 | 1996 | 1428 | 0.020 |
Why?
|
| Pulmonary Circulation | 2 | 1982 | 744 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2012 | 1952 | 0.020 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2007 | 91 | 0.020 |
Why?
|
| Ferricyanides | 1 | 1987 | 31 | 0.020 |
Why?
|
| Antibodies, Viral | 2 | 2010 | 3211 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2008 | 363 | 0.020 |
Why?
|
| Logistic Models | 3 | 2011 | 13323 | 0.020 |
Why?
|
| Fatty Acids | 2 | 1988 | 1815 | 0.020 |
Why?
|
| Vitamin D-Binding Protein | 1 | 1988 | 130 | 0.020 |
Why?
|
| Acute Disease | 3 | 2008 | 7242 | 0.020 |
Why?
|
| X-Ray Diffraction | 1 | 2008 | 417 | 0.020 |
Why?
|
| Tachycardia | 1 | 1990 | 598 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2009 | 526 | 0.020 |
Why?
|
| Renin-Angiotensin System | 1 | 1992 | 739 | 0.020 |
Why?
|
| Myocardial Reperfusion | 1 | 1988 | 339 | 0.020 |
Why?
|
| Young Adult | 5 | 2013 | 60049 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2013 | 1026 | 0.020 |
Why?
|
| Ventricular Fibrillation | 1 | 1990 | 537 | 0.020 |
Why?
|
| Quinolines | 1 | 1992 | 768 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2009 | 473 | 0.020 |
Why?
|
| Tantalum | 1 | 1987 | 54 | 0.020 |
Why?
|
| Israel | 1 | 2009 | 726 | 0.020 |
Why?
|
| Heart Failure | 6 | 1992 | 11858 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 1669 | 0.020 |
Why?
|
| Catalysis | 1 | 2008 | 768 | 0.020 |
Why?
|
| Medically Underserved Area | 1 | 2008 | 266 | 0.020 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 1987 | 213 | 0.020 |
Why?
|
| Social Behavior | 1 | 2013 | 1146 | 0.020 |
Why?
|
| Rabbits | 2 | 1990 | 4781 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1993 | 3813 | 0.020 |
Why?
|
| RNA Polymerase II | 1 | 2010 | 547 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2008 | 611 | 0.020 |
Why?
|
| Hemophilia A | 1 | 1989 | 359 | 0.020 |
Why?
|
| Respiratory System | 1 | 2009 | 565 | 0.020 |
Why?
|
| Neopterin | 2 | 1996 | 57 | 0.020 |
Why?
|
| Patient Compliance | 2 | 2008 | 2693 | 0.020 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 1990 | 881 | 0.020 |
Why?
|
| Drug Evaluation | 3 | 1996 | 642 | 0.020 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1990 | 775 | 0.020 |
Why?
|
| Sarcoma, Kaposi | 1 | 1988 | 374 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 1998 | 4209 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 1995 | 10776 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 1989 | 648 | 0.020 |
Why?
|
| Bronchi | 1 | 2009 | 849 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1992 | 1517 | 0.020 |
Why?
|
| Mannitol | 1 | 1985 | 177 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 2482 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 2353 | 0.010 |
Why?
|
| Odds Ratio | 2 | 2009 | 9682 | 0.010 |
Why?
|
| Pericardium | 1 | 1989 | 679 | 0.010 |
Why?
|
| Remission Induction | 1 | 2010 | 2407 | 0.010 |
Why?
|
| Pressure | 2 | 1989 | 1172 | 0.010 |
Why?
|
| Information Storage and Retrieval | 1 | 2010 | 824 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 863 | 0.010 |
Why?
|
| Genetics | 1 | 2005 | 114 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 2005 | 368 | 0.010 |
Why?
|
| Disease Models, Animal | 4 | 2011 | 18362 | 0.010 |
Why?
|
| Antibody Specificity | 2 | 1998 | 1065 | 0.010 |
Why?
|
| Molecular Mimicry | 1 | 2005 | 213 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 1995 | 2986 | 0.010 |
Why?
|
| China | 1 | 2010 | 2395 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1988 | 992 | 0.010 |
Why?
|
| Community Health Services | 1 | 2009 | 659 | 0.010 |
Why?
|
| Angina Pectoris, Variant | 1 | 1983 | 53 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 2003 | 114 | 0.010 |
Why?
|
| Sodium Pertechnetate Tc 99m | 1 | 1983 | 54 | 0.010 |
Why?
|
| Aging | 1 | 2002 | 8764 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 1995 | 5801 | 0.010 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1987 | 746 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 1629 | 0.010 |
Why?
|
| Gene Frequency | 2 | 2000 | 3617 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1998 | 4300 | 0.010 |
Why?
|
| Cell Fusion | 2 | 1997 | 294 | 0.010 |
Why?
|
| Trachea | 1 | 2009 | 1095 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 2013 | 2200 | 0.010 |
Why?
|
| Databases as Topic | 1 | 2005 | 475 | 0.010 |
Why?
|
| Ambulatory Care | 3 | 1988 | 2784 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2010 | 1748 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2001 | 5713 | 0.010 |
Why?
|
| Albumins | 1 | 1985 | 577 | 0.010 |
Why?
|
| Macrophages | 1 | 1997 | 5796 | 0.010 |
Why?
|
| HIV-2 | 2 | 1993 | 156 | 0.010 |
Why?
|
| Withholding Treatment | 1 | 2006 | 620 | 0.010 |
Why?
|
| ROC Curve | 1 | 2010 | 3623 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 1989 | 1322 | 0.010 |
Why?
|
| Tellurium | 1 | 1982 | 23 | 0.010 |
Why?
|
| Isotonic Solutions | 1 | 1982 | 120 | 0.010 |
Why?
|
| Rural Population | 1 | 2013 | 2318 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 1993 | 2139 | 0.010 |
Why?
|
| Genes, Viral | 1 | 2003 | 655 | 0.010 |
Why?
|
| Potassium | 2 | 1985 | 1318 | 0.010 |
Why?
|
| Constriction, Pathologic | 3 | 1994 | 1104 | 0.010 |
Why?
|
| Heart Block | 1 | 1983 | 390 | 0.010 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1983 | 389 | 0.010 |
Why?
|
| Influenza Vaccines | 1 | 2009 | 780 | 0.010 |
Why?
|
| Imidazoles | 1 | 1987 | 1168 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1997 | 19022 | 0.010 |
Why?
|
| Extracorporeal Circulation | 1 | 1981 | 181 | 0.010 |
Why?
|
| Injections, Subcutaneous | 2 | 1995 | 687 | 0.010 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2000 | 111 | 0.010 |
Why?
|
| Spain | 1 | 2002 | 492 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1988 | 2204 | 0.010 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2001 | 93 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 2000 | 165 | 0.010 |
Why?
|
| Exercise Therapy | 1 | 1986 | 941 | 0.010 |
Why?
|
| Age Factors | 2 | 1989 | 18471 | 0.010 |
Why?
|
| Linear Models | 1 | 2009 | 5878 | 0.010 |
Why?
|
| Mathematics | 1 | 2000 | 704 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2012 | 3627 | 0.010 |
Why?
|
| Drug Resistance | 2 | 1996 | 1595 | 0.010 |
Why?
|
| Aorta | 1 | 1987 | 2046 | 0.010 |
Why?
|
| Swine | 1 | 2009 | 5994 | 0.010 |
Why?
|
| Anemia, Aplastic | 1 | 2001 | 231 | 0.010 |
Why?
|
| Body Weight | 1 | 2010 | 4629 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 2000 | 607 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 7861 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 784 | 0.010 |
Why?
|
| Primates | 1 | 2001 | 521 | 0.010 |
Why?
|
| Family Practice | 1 | 2001 | 511 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1995 | 1855 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2000 | 518 | 0.010 |
Why?
|
| Leukemia, Myeloid | 1 | 2001 | 693 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2005 | 2673 | 0.010 |
Why?
|
| Pilot Projects | 2 | 2003 | 8731 | 0.010 |
Why?
|
| Radiography | 4 | 1983 | 6993 | 0.010 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1998 | 141 | 0.010 |
Why?
|
| Internet | 1 | 2010 | 3107 | 0.010 |
Why?
|
| Gelatin | 1 | 1999 | 231 | 0.010 |
Why?
|
| Heart Aneurysm | 1 | 1977 | 114 | 0.010 |
Why?
|
| Deoxyribonucleosides | 1 | 1996 | 7 | 0.010 |
Why?
|
| Structure-Activity Relationship | 2 | 1993 | 3055 | 0.010 |
Why?
|
| Magnesium Chloride | 1 | 1996 | 30 | 0.010 |
Why?
|
| Candida albicans | 1 | 2000 | 375 | 0.010 |
Why?
|
| Pulmonary Valve Stenosis | 1 | 1977 | 164 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 1998 | 269 | 0.010 |
Why?
|
| Poverty | 1 | 2008 | 2721 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1983 | 1882 | 0.010 |
Why?
|
| Patient Discharge | 1 | 1989 | 3476 | 0.010 |
Why?
|
| Threonine | 1 | 1997 | 274 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2001 | 687 | 0.010 |
Why?
|
| Stress, Psychological | 2 | 1989 | 4543 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2009 | 22296 | 0.010 |
Why?
|
| AIDS-Related Complex | 1 | 1995 | 107 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1994 | 11918 | 0.010 |
Why?
|
| Protein Binding | 1 | 2008 | 9343 | 0.010 |
Why?
|
| Mass Screening | 1 | 2011 | 5451 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1999 | 765 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1989 | 4785 | 0.010 |
Why?
|
| Trinucleotide Repeats | 1 | 1996 | 257 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1996 | 350 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1996 | 313 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1988 | 4505 | 0.010 |
Why?
|
| Patient Selection | 1 | 2007 | 4266 | 0.010 |
Why?
|
| Injections, Intravenous | 2 | 1990 | 1379 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1996 | 366 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1996 | 564 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 1988 | 3300 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1996 | 781 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1995 | 513 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 1996 | 715 | 0.010 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 1976 | 452 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 1998 | 1696 | 0.010 |
Why?
|
| Ribonuclease H | 1 | 1993 | 52 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 4479 | 0.010 |
Why?
|
| Survival Rate | 2 | 2001 | 12870 | 0.010 |
Why?
|
| Antigenic Variation | 1 | 1993 | 118 | 0.010 |
Why?
|
| Tissue Survival | 1 | 1992 | 120 | 0.010 |
Why?
|
| Kidney | 1 | 2008 | 7064 | 0.010 |
Why?
|
| Treatment Refusal | 1 | 1996 | 432 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2001 | 4834 | 0.010 |
Why?
|
| Microspheres | 2 | 1988 | 789 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1993 | 1142 | 0.010 |
Why?
|
| Tetralogy of Fallot | 1 | 1977 | 628 | 0.010 |
Why?
|
| Papillomaviridae | 1 | 1998 | 1140 | 0.010 |
Why?
|
| Mice | 4 | 2007 | 82017 | 0.010 |
Why?
|
| Creatine Kinase | 2 | 1985 | 685 | 0.010 |
Why?
|
| Pulmonary Veins | 1 | 1977 | 754 | 0.010 |
Why?
|
| Life Tables | 1 | 1991 | 368 | 0.010 |
Why?
|
| Atrial Function, Right | 1 | 1991 | 32 | 0.010 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 1 | 1991 | 26 | 0.010 |
Why?
|
| Gene Products, rev | 1 | 1991 | 29 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2005 | 6277 | 0.010 |
Why?
|
| United States | 2 | 2011 | 73150 | 0.010 |
Why?
|
| Plasmids | 1 | 1996 | 2268 | 0.010 |
Why?
|
| Gene Products, nef | 1 | 1991 | 102 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 1996 | 1093 | 0.010 |
Why?
|
| Gene Products, tat | 1 | 1991 | 111 | 0.010 |
Why?
|
| Methionine | 1 | 1993 | 573 | 0.010 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 1991 | 120 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1999 | 6241 | 0.010 |
Why?
|
| AIDS Vaccines | 1 | 1997 | 900 | 0.010 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 1991 | 149 | 0.010 |
Why?
|
| Viral Core Proteins | 1 | 1991 | 158 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1996 | 1339 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 706 | 0.010 |
Why?
|
| Monitoring, Physiologic | 2 | 1988 | 1795 | 0.010 |
Why?
|
| Refractory Period, Electrophysiological | 1 | 1990 | 40 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 17135 | 0.010 |
Why?
|
| Africa, Eastern | 1 | 1989 | 76 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1993 | 1229 | 0.010 |
Why?
|
| Africa, Western | 1 | 1989 | 160 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1988 | 5857 | 0.010 |
Why?
|
| Serotyping | 1 | 1989 | 332 | 0.000 |
Why?
|
| Isoelectric Focusing | 1 | 1988 | 149 | 0.000 |
Why?
|
| Isoenzymes | 2 | 1985 | 1684 | 0.000 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 1991 | 579 | 0.000 |
Why?
|
| Fatigue | 1 | 1996 | 1555 | 0.000 |
Why?
|
| Tanzania | 1 | 1993 | 1403 | 0.000 |
Why?
|
| Rats, Inbred BN | 1 | 1988 | 231 | 0.000 |
Why?
|
| Lung Diseases | 1 | 1998 | 1925 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1996 | 2938 | 0.000 |
Why?
|
| Forecasting | 1 | 1997 | 2948 | 0.000 |
Why?
|
| Flow Cytometry | 1 | 1998 | 5900 | 0.000 |
Why?
|
| Palpation | 1 | 1988 | 166 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 11221 | 0.000 |
Why?
|
| Myocardial Revascularization | 1 | 1991 | 796 | 0.000 |
Why?
|
| Enoximone | 1 | 1987 | 9 | 0.000 |
Why?
|
| Postoperative Period | 1 | 1992 | 1830 | 0.000 |
Why?
|
| Osmolar Concentration | 1 | 1988 | 657 | 0.000 |
Why?
|
| Cardiac Volume | 1 | 1988 | 197 | 0.000 |
Why?
|
| Colitis | 1 | 1996 | 1244 | 0.000 |
Why?
|
| Models, Structural | 1 | 1987 | 340 | 0.000 |
Why?
|
| Elasticity | 1 | 1989 | 657 | 0.000 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1994 | 1724 | 0.000 |
Why?
|
| Iatrogenic Disease | 1 | 1990 | 552 | 0.000 |
Why?
|
| Choristoma | 1 | 1988 | 205 | 0.000 |
Why?
|
| Rats, Inbred Lew | 1 | 1988 | 1165 | 0.000 |
Why?
|
| Papillomavirus Infections | 1 | 1998 | 1640 | 0.000 |
Why?
|
| Hypertonic Solutions | 1 | 1985 | 82 | 0.000 |
Why?
|
| Tomography, Emission-Computed | 1 | 1988 | 1126 | 0.000 |
Why?
|
| Clinical Competence | 1 | 2001 | 4848 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1988 | 2559 | 0.000 |
Why?
|
| Immunoassay | 1 | 1988 | 745 | 0.000 |
Why?
|
| Death, Sudden, Cardiac | 1 | 1993 | 1568 | 0.000 |
Why?
|
| Weight Loss | 1 | 1996 | 2713 | 0.000 |
Why?
|
| Chromatin | 1 | 1996 | 2968 | 0.000 |
Why?
|
| Cold Temperature | 1 | 1988 | 786 | 0.000 |
Why?
|
| Multicenter Studies as Topic | 1 | 1989 | 1727 | 0.000 |
Why?
|
| Antibody Formation | 1 | 1988 | 1393 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1995 | 8562 | 0.000 |
Why?
|
| Multiple Myeloma | 1 | 2001 | 5192 | 0.000 |
Why?
|
| Immunity, Cellular | 1 | 1988 | 1561 | 0.000 |
Why?
|
| Tin | 1 | 1982 | 13 | 0.000 |
Why?
|
| Scandium | 1 | 1982 | 7 | 0.000 |
Why?
|
| Isotopes | 1 | 1982 | 125 | 0.000 |
Why?
|
| Quality of Life | 1 | 2003 | 13503 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1982 | 363 | 0.000 |
Why?
|
| Radiation Monitoring | 1 | 1982 | 106 | 0.000 |
Why?
|
| Eating | 1 | 1988 | 1541 | 0.000 |
Why?
|
| Radiation Dosage | 1 | 1989 | 1974 | 0.000 |
Why?
|
| Survival Analysis | 1 | 1993 | 10117 | 0.000 |
Why?
|
| Radioisotope Dilution Technique | 1 | 1979 | 71 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1989 | 2421 | 0.000 |
Why?
|
| Activities of Daily Living | 1 | 1988 | 2433 | 0.000 |
Why?
|
| Postoperative Care | 1 | 1985 | 1480 | 0.000 |
Why?
|
| Cell Survival | 1 | 1988 | 5792 | 0.000 |
Why?
|
| Angiocardiography | 1 | 1977 | 149 | 0.000 |
Why?
|
| Graft Survival | 1 | 1988 | 3900 | 0.000 |
Why?
|
| Hypothermia, Induced | 1 | 1982 | 756 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1988 | 4570 | 0.000 |
Why?
|
| Intraoperative Complications | 1 | 1982 | 1176 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 1996 | 26375 | 0.000 |
Why?
|
| Posture | 1 | 1979 | 956 | 0.000 |
Why?
|
| Ultrasonography | 1 | 1988 | 6001 | 0.000 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1982 | 1414 | 0.000 |
Why?
|
| Rats | 1 | 1988 | 23835 | 0.000 |
Why?
|